

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**三生制药**  
**3SBIO INC.**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1530)**

**(Convertible Bonds Code: 40285)**

## **DELAY IN DESPATCH OF CIRCULAR**

Reference is made to the announcement of 3SBio Inc. dated 8 September 2020 in relation to the conditional grant of new Awarded Shares pursuant to the Scheme (the “**Announcement**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, a circular (the “**Circular**”), containing, amongst other things, (i) further details of the Grant; (ii) the Specific Mandate; (iii) the letter of recommendation from the Independent Board Committee in respect of the Grant and the Specific Mandate; (iv) the letter of advice from the Independent Financial Adviser in respect of the Grant and the Specific Mandate; (v) a notice convening the EGM; and (vi) other information as required under the Listing Rules is expected to be despatched to the Shareholders and posted on the website of the Stock Exchange (<http://www.hkexnews.hk>) and the website of the Company (<http://www.3sbio.com>) on or before 9 October 2020.

As additional time is required to finalise the information to be included in the Circular, it is expected that the Circular will be despatched as soon as practicable on or before 16 October 2020.

By order of the Board  
**3SBio Inc.**  
**Dr. LOU Jing**  
*Chairman*

Shenyang, the PRC  
9 October 2020

*As at the date of this announcement, the directors of the Company are Dr. LOU Jing and Ms. SU Dongmei as executive directors; Mr. HUANG Bin and Mr. TANG Ke as non-executive directors; and Mr. PU Tianruo, Mr. David Ross PARKINSON and Dr. WONG Lap Yan as independent non-executive directors.*